RedHill Biopharma (NASDAQ:RDHL) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Stock Performance

RDHL stock opened at $2.41 on Monday. RedHill Biopharma has a 1-year low of $1.80 and a 1-year high of $20.28. The business has a 50-day moving average price of $3.54 and a 200 day moving average price of $5.95.

Hedge Funds Weigh In On RedHill Biopharma

An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC bought a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma as of its most recent SEC filing. 7.20% of the stock is currently owned by institutional investors.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.